Volume 14 Issue 3
May  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(3): 371-378
Guo Wenwen, Yuan Yuan, Wang Hao, et al. Protective role and mechanism of human umbilical cord mesenchymal stem cell-derived exosome in renal ischemia-reperfusion injury[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 371-378. doi: 10.3969/j.issn.1674-7445.2023.03.008
Citation: Guo Wenwen, Yuan Yuan, Wang Hao, et al. Protective role and mechanism of human umbilical cord mesenchymal stem cell-derived exosome in renal ischemia-reperfusion injury[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 371-378. doi: 10.3969/j.issn.1674-7445.2023.03.008
shu

Protective role and mechanism of human umbilical cord mesenchymal stem cell-derived exosome in renal ischemia-reperfusion injury

doi: 10.3969/j.issn.1674-7445.2023.03.008

  • The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

More Information
  • Corresponding author: Lyu Xinghua, Email: ldyyrjsszx1214@163.com
  • Received Date: 2023-02-12
  • Publish Date: 2023-05-15
    Abstract
  •   Objective  To investigate the protective effect of human umbilical cord mesenchymal stem cell-derived exosome (hucMSC-Exo) on renal ischemia-reperfusion injury (IRI), and to clarify the critical role and regulating mechanism of transient receptor potential canonical (TRPC) 6/poly adenosine-diphosphate-ribose polymerase (PARP) 1 signaling pathway during this process.  Methods  The hucMSC-Exo was extracted by ultracentrifugation, and identified by transmission electron microscope (TEM), nanoparticle tracing analysis and Western blot. SD rats were randomly divided into the sham operation group (group S), sham operation+TRPC6 inhibitor SKF96365 group (group SS), renal IRI group (group IRI), exosome treatment group (group EXO) and exosome +TRPC6 inhibitor SKF96365 group (group ES), with 6 rats in each group. Serum creatinine and blood urea nitrogen levels were detected. Pathological changes of renal tissues were observed by hematoxylin-eosin (HE) staining and Paller score was calculated. The expression levels of key molecules of necroptosis in rat renal tissues, including receptor-interacting protein kinase (RIPK)1, RIPK3 and mixed-lineage kinase domain-like protein (MLKL), TRPC6 and PARP1, were detected by Western blot.  Results  Typical saucer-like structure was observed under TEM. Nanoparticle tracing analysis showed that the average diameter of the extracted substance was 125.9 nm. Western blot revealed that the surface markers of CD9, CD63 and CD81 were positively expressed, confirmed that the extracted substance was exosome. Compared with group S, the serum creatinine and blood urea nitrogen levels were up-regulated, the pathological damage of renal tissues was worsened, Paller score was elevated, the relative expression levels of TRPC6 and PARP1 proteins were down-regulated, and the relative expression levels of RIPK1, RIPK3 and MLKL proteins were up-regulated in group IRI (all P < 0.05). Compared with group IRI, the serum creatinine and blood urea nitrogen levels were down-regulated, the pathological damage of renal tissues was mitigated, Paller score was decreased, the relative expression levels of TRPC6 and PARP1 proteins were up-regulated, and the relative expression levels of RIPK1, RIPK3 and MLKL proteins were down-regulated in group EXO (all P < 0.05). Compared with group EXO, the serum creatinine and blood urea nitrogen levels were up-regulated, the pathological damage of renal tissues was aggravated, Paller score was increased, the relative expression levels of TRPC6 and PARP1 proteins were down-regulated, and the relative expression levels of RIPK1, RIPK3 and MLKL proteins were up-regulated in group ES (all P < 0.05).  Conclusions  hucMSC-Exo may alleviate the necroptosis induced by renal IRI in rat models, which is related to the activation of TRPC6/PARP1 signaling pathway.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    THAPA K, SINGH TG, KAUR A. Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury[J]. Life Sci, 2021, 282: 119843. DOI: 10.1016/j.lfs.2021.119843.
    [2]
    G BARDALLO R, PANISELLO-ROSELLÓ A, SANCHEZ-NUNO S, et al. Nrf2 and oxidative stress in liver ischemia/reperfusion injury[J]. FEBS J, 2022, 289(18): 5463-5479. DOI: 10.1111/febs.16336.
    [3]
    WU MY, YIANG GT, LIAO WT, et al. Current mechanistic concepts in ischemia and reperfusion injury[J]. Cell Physiol Biochem, 2018, 46(4): 1650-1667. DOI: 10.1159/000489241.
    [4]
    MARTIN JL, GRUSZCZYK AV, BEACH TE, et al. Mitochondrial mechanisms and therapeutics in ischaemia reperfusion injury[J]. Pediatr Nephrol, 2019, 34(7): 1167-1174. DOI: 10.1007/s00467-018-3984-5.
    [5]
    JUN W, BENJANUWATTRA J, CHATTIPAKORN SC, et al. Necroptosis in renal ischemia/reperfusion injury: a major mode of cell death?[J]. Arch Biochem Biophys, 2020, 689: 108433. DOI: 10.1016/j.abb.2020.108433.
    [6]
    FENG Y, IMAM ALIAGAN A, TOMBO N, et al. RIP3 translocation into mitochondria promotes mitofilin degradation to increase inflammation and kidney injury after renal ischemia-reperfusion[J]. Cells, 2022, 11(12): 1894. DOI: 10.3390/cells11121894.
    [7]
    SHEN B, HE Y, ZHOU S, et al. TRPC6 may protect renal ischemia-reperfusion injury through inhibiting necroptosis of renal tubular epithelial cells[J]. Med Sci Monit, 2016, 22: 633-641. DOI: 10.12659/msm.897353.
    [8]
    HUANG J, CAO H, CUI B, et al. Mesenchymal stem cells-derived exosomes ameliorate ischemia/reperfusion induced acute kidney injury in a porcine model[J]. Front Cell Dev Biol, 2022, 10: 899869. DOI: 10.3389/fcell.2022.899869.
    [9]
    DING C, ZHENG J, WANG B, et al. Exosomal microRNA-374b-5p from tubular epithelial cells promoted M1 macrophages activation and worsened renal ischemia/reperfusion injury[J]. Front Cell Dev Biol, 2020, 8: 587693. DOI: 10.3389/fcell.2020.587693.
    [10]
    ZHANG Y, WANG J, YANG B, et al. Transfer of microRNA-216a-5p from exosomes secreted by human urine-derived stem cells reduces renal ischemia/reperfusion injury[J]. Front Cell Dev Biol, 2020, 8: 610587. DOI: 10.3389/fcell.2020.610587.
    [11]
    SHEN B, MEI M, PU Y, et al. Necrostatin-1 attenuates renal ischemia and reperfusion injury via meditation of HIF-1α/miR-26a/TRPC6/PARP1 signaling[J]. Mol Ther Nucleic Acids, 2019, 17: 701-713. DOI: 10.1016/j.omtn.2019.06.025.
    [12]
    ZHANG Y, CHANG Y, HAN Z, et al. Estrogen protects against renal ischemia-reperfusion injury by regulating Th17/Treg cell immune balance[J]. Dis Markers, 2022: 7812099. DOI: 10.1155/2022/7812099.
    [13]
    ZHOU Z, YOU B, JI C, et al. Implications of crosstalk between exosome-mediated ferroptosis and diseases for pathogenesis and treatment[J]. Cells, 2023, 12(2): 311. DOI: 10.3390/cells12020311.
    [14]
    LIN Z, WU Y, XU Y, et al. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential[J]. Mol Cancer, 2022, 21(1): 179. DOI: 10.1186/s12943-022-01650-5.
    [15]
    LAI JJ, CHAU ZL, CHEN SY, et al. Exosome processing and characterization approaches for research and technology development[J]. Adv Sci (Weinh), 2022, 9(15): e2103222. DOI: 10.1002/advs.202103222.
    [16]
    KEERTHIKUMAR S, CHISANGA D, ARIYARATNE D, et al. ExoCarta: a web-based compendium of exosomal cargo[J]. J Mol Biol, 2016, 428(4): 688-692. DOI: 10.1016/j.jmb.2015.09.019.
    [17]
    HU Q, SU H, LI J, et al. Clinical applications of exosome membrane proteins[J]. Precis Clin Med, 2020, 3(1): 54-66. DOI: 10.1093/pcmedi/pbaa007.
    [18]
    SOHRABI B, DAYERI B, ZAHEDI E, et al. Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy[J]. Cancer Gene Ther, 2022, 29(8/9): 1105-1116. DOI: 10.1038/s41417-022-00427-8.
    [19]
    CHEN S, SUN F, QIAN H, et al. Preconditioning and engineering strategies for improving the efficacy of mesenchymal stem cell-derived exosomes in cell-free therapy[J]. Stem Cells Int, 2022: 1779346. DOI: 10.1155/2022/1779346.
    [20]
    KIMIZ-GEBOLOGLU I, ONCEL SS. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake[J]. J Control Release, 2022, 347: 533-543. DOI: 10.1016/j.jconrel.2022.05.027.
    [21]
    FERREIRA D, MOREIRA JN, RODRIGUES LR. New advances in exosome-based targeted drug delivery systems[J]. Crit Rev Oncol Hematol, 2022, 172: 103628. DOI: 10.1016/j.critrevonc.2022.103628.
    [22]
    王光华, 王桂斌, 滕晓华. 间充质干细胞来源外泌体治疗缺血再灌注损伤分子机制及研究进展[J]. 生物医学工程与临床, 2021, 25(5): 639-643. DOI: 10.13339/j.cnki.sglc.20210820.019.

    WANG GH, WANG GB, TENG XH. Review of exosomes derived from mesenchymal stem cells in protecting ischemia-reperfusion injury[J]. Biomed Eng Clin Med, 2021, 25(5): 639-643. DOI: 10.13339/j.cnki.sglc.20210820.019.
    [23]
    LIAO YJ, MA YX, HUANG LL, et al. Augmenter of liver regeneration protects the kidney against ischemia-reperfusion injury by inhibiting necroptosis[J]. Bioengineered, 2022, 13(3): 5152-5167. DOI: 10.1080/21655979.2022.2037248.
    [24]
    刘昕蓓, 刘文静. 调控性细胞死亡在肾脏缺血再灌注损伤中的研究进展[J]. 生理学报, 2022, 74(2): 320-332. DOI: 10.13294/j.aps.2022.0025.

    LIU XB, LIU WJ. The role of regulated cell death in renal ischemia-reperfusion injury[J]. Acta Physiol Sin, 2022, 74(2): 320-332. DOI: 10.13294/j.aps.2022.0025.
    [25]
    DEGTEREV A, HUANG Z, BOYCE M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury[J]. Nat Chem Biol, 2005, 1(2): 112-119. DOI: 10.1038/nchembio711.
    [26]
    DELLA TORRE L, NEBBIOSO A, STUNNENBERG HG, et al. The role of necroptosis: biological relevance and its involvement in cancer[J]. Cancers (Basel), 2021, 13(4): 684. DOI: 10.3390/cancers13040684.
    [27]
    ASHOUR H, HASHEM HA, KHOWAILED AA, et al. Necrostatin-1 mitigates renal ischaemia-reperfusion injury - time dependent - via aborting the interacting protein kinase (RIPK-1)-induced inflammatory immune response[J]. Clin Exp Pharmacol Physiol, 2022, 49(4): 501-514. DOI: 10.1111/1440-1681.13625.
    [28]
    LIU Z, LI C, LI Y, et al. Propofol reduces renal ischemia reperfusion-mediated necroptosis by up-regulation of SIRT1 in rats[J]. Inflammation, 2022, 45(5): 2038-2051. DOI: 10.1007/s10753-022-01673-6.
    [29]
    YUAN X, LI D, CHEN X, et al. Extracellular vesicles from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect against renal ischemia/reperfusion injury via delivering specificity protein (SP1) and transcriptional activating of sphingosine kinase 1 and inhibiting necroptosis[J]. Cell Death Dis, 2017, 8(12): 3200. DOI: 10.1038/s41419-017-0041-4.
    [30]
    WANG H, CHENG X, TIAN J, et al. TRPC channels: structure, function, regulation and recent advances in small molecular probes[J]. Pharmacol Ther, 2020, 209: 107497. DOI: 10.1016/j.pharmthera.2020.107497.
    [31]
    ENGLISCH CN, PAULSEN F, TSCHERNIG T. TRPC channels in the physiology and pathophysiology of the renal tubular system: what do we know?[J]. Int J Mol Sci, 2022, 24(1): 181. DOI: 10.3390/ijms24010181.
    [32]
    DRYER SE, KIM EY. The effects of TRPC6 knockout in animal models of kidney disease[J]. Biomolecules, 2022, 12(11): 1710. DOI: 10.3390/biom12111710.
    [33]
    郭文文, 袁圆, 魏华锋, 等. 瞬时受体电位阳离子通道蛋白6在缺血-再灌注损伤中的作用研究进展[J]. 器官移植, 2022, 13(5): 659-665. DOI: 10.3969/j.issn.1674-7445.2022.05.017.

    GUO WW, YUAN Y, WEI HF, et al. Research progress on the role of transient receptor potential canonical 6 in ischemia-reperfusion injury[J]. Organ Transplant, 2022, 13(5): 659-665. DOI: 10.3969/j.issn.1674-7445.2022.05.017.
    [34]
    ZHENG Z, TSVETKOV D, BARTOLOMAEUS TUP, et al. Role of TRPC6 in kidney damage after acute ischemic kidney injury[J]. Sci Rep, 2022, 12(1): 3038. DOI: 10.1038/s41598-022-06703-9.
    [35]
    SHEN B, MEI M, AI S, et al. TRPC6 inhibits renal tubular epithelial cell pyroptosis through regulating zinc influx and alleviates renal ischemia-reperfusion injury[J]. FASEB J, 2022, 36(10): e22527. DOI: 10.1096/fj.202200109RR.
    [36]
    PU Y, ZHAO H, SHEN B, et al. TRPC6 ameliorates renal ischemic reperfusion injury by inducing Zn2+ influx and activating autophagy to resist necrosis[J]. Ann Transl Med, 2022, 10(5): 249. DOI: 10.21037/atm-21-5837.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (401) PDF downloads(48) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return